KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib
John Smith(Wycombe General Hospital), Juliane M. Jürgensmeier(AstraZeneca (United Kingdom)), David M. Wilson(AstraZeneca (Singapore)), Shethah Morgan(AstraZeneca (United Kingdom)), Gael McWalter(AstraZeneca (United Kingdom)), Paulo M. Hoff(Translational Research in Oncology), Laura Brooks(University of North Carolina at Chapel Hill), Jane Robertson(Cancer Research UK), Simon Dearden(AstraZeneca (United Kingdom))
Cited by 16
Related Papers
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial
|The Lancet Oncology|2012|526
Genetic assessment of age-associated Alzheimer disease risk: Development and validation of a polygenic hazard score
|PLoS Medicine|2017|410
Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid Tumors
|Journal of Clinical Oncology|2007|303